Oragenics dosed first patient in Phase IIa concussion trial; signs LOI for CNS device

ORAGENICS INC

Phase IIa trial of ONP-002 in Australia active; first patient dosed at Mackay Base Hospital March 2026.
Signed LOI to license a complementary CNS medical device; expands addressable indication set beyond ONP-002.
Cash balance $6.1M as of Q1 2026; R&D expenses $0.6M (up 89% YoY); G&A $1.6M (down 4% YoY).
Targets Type C meeting with FDA in Q2 2026, IND submission by end of 2026, Phase IIa data readout in 2026.

item 7.01item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.